Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALNY Stock Forecast 2025-2026
$289.96
Current Price
$37.47B
Market Cap
Buy 24
Hold 7
Sell 2
Wall St Analyst Ratings
Distance to ALNY Price Targets
+72.4%
To High Target of $500.00
+13.1%
To Median Target of $328.00
-26.9%
To Low Target of $212.00
ALNY Price Momentum
+1.6%
1 Week Change
+19.5%
1 Month Change
+96.2%
1 Year Change
+23.2%
Year-to-Date Change
-4.7%
From 52W High of $304.39
+97.5%
From 52W Low of $146.79
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Alnylam (ALNY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALNY and similar high-potential opportunities.
Latest ALNY Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, ALNY has a bullish consensus with a median price target of $328.00 (ranging from $212.00 to $500.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $289.96, the median forecast implies a 13.1% upside. This outlook is supported by 24 Buy, 7 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 72.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALNY Analyst Ratings
24
Buy
7
Hold
2
Sell
ALNY Price Target Range
Low
$212.00
Average
$328.00
High
$500.00
Current: $289.96
Latest ALNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $325.00 |
| May 2, 2025 | UBS | Esther Rajavelu | Buy | Maintains | $349.00 |
| Apr 11, 2025 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $268.00 |
| Apr 9, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $320.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $500.00 |
| Mar 31, 2025 | Redburn Atlantic | Joshua Smith | Buy | Initiates | $353.00 |
| Mar 31, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $342.00 |
| Mar 31, 2025 | Stifel | Paul Matteis | Buy | Maintains | $345.00 |
| Mar 24, 2025 | JP Morgan | Jessica Fye | Overweight | Upgrade | $328.00 |
| Mar 21, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $320.00 |
| Mar 21, 2025 | Wells Fargo | Tiago Fauth | Equal-Weight | Maintains | $287.00 |
| Mar 21, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $338.00 |
| Mar 21, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $330.00 |
| Mar 21, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $325.00 |
| Mar 21, 2025 | Citigroup | David Lebovitz | Buy | Maintains | $351.00 |
| Mar 21, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $390.00 |
| Mar 21, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $300.00 |
| Mar 11, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $280.00 |
| Feb 26, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $300.00 |
| Feb 26, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $310.00 |
Alnylam Pharmaceuticals Inc. (ALNY) Competitors
The following stocks are similar to Alnylam based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alnylam Pharmaceuticals Inc. (ALNY) Financial Data
Alnylam Pharmaceuticals Inc. has a market capitalization of $37.47B with a P/E ratio of 0.0x. The company generates $2.35B in trailing twelve-month revenue with a -11.5% profit margin.
Revenue growth is +20.2% quarter-over-quarter, while maintaining an operating margin of +3.0% and return on equity of -414.6%.
Valuation Metrics
Market Cap
$37.47B
Enterprise Value
$38.24B
P/E Ratio
0.0x
PEG Ratio
-235.6x
Price/Sales
16.0x
Growth & Margins
Revenue Growth (YoY)
+20.2%
Gross Margin
+88.0%
Operating Margin
+3.0%
Net Margin
-11.5%
EPS Growth
+20.2%
Financial Health
Cash/Price Ratio
+7.0%
Current Ratio
3.0x
Debt/Equity
2,358.3x
ROE
-414.6%
ROA
-1.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Alnylam Pharmaceuticals Inc. (ALNY) Business Model
About Alnylam Pharmaceuticals Inc.
What They Do
Develops RNA interference therapeutics for diseases.
Business Model
Alnylam Pharmaceuticals leverages RNA interference (RNAi) technology to create innovative treatments that target and silence specific genes associated with various diseases. The company generates revenue through the development and commercialization of its therapeutics, as well as partnerships and collaborations with other pharmaceutical entities.
Additional Information
With a focus on genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, Alnylam is positioned as a leader in biotechnology. The company is headquartered in Cambridge, Massachusetts, and is actively advancing its pipeline of therapeutics to address previously untreatable conditions, reflecting its commitment to transforming modern medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,230
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Country
United States
IPO Year
2004
Website
www.alnylam.comAlnylam Pharmaceuticals Inc. (ALNY) Latest News & Analysis
Latest News
Quick Summary
Alnylam Pharmaceuticals published its 2024 Corporate Responsibility Report, emphasizing its commitment to patient access and progress in health across six responsibility pillars.
Why It Matters
Alnylam's Corporate Responsibility Report showcases its commitment to patient access and health improvement, potentially enhancing its reputation and attracting socially-conscious investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alnylam Pharmaceuticals presented new insights from the HELIOS-B Phase 3 study on vutrisiran for ATTR-CM at the Heart Failure 2025 Congress, highlighting its therapeutic potential.
Why It Matters
Positive results from the HELIOS-B Phase 3 study of vutrisiran could enhance Alnylam's market position and drive stock performance, influencing investment decisions in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alnylam Pharmaceuticals will present new data on its TTR franchise at the Heart Failure 2025 Congress, scheduled for May 17-20 in Belgrade, focusing on the HELIOS-B Phase 3 study of vutrisiran.
Why It Matters
Alnylam Pharmaceuticals' presentation of pivotal data on vutrisiran at a major conference could influence stock performance, reflecting advancements in their TTR franchise and potential market impact.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alnylam Pharmaceuticals will present a company overview at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 11:20 am PT. A live webcast will be available on their website.
Why It Matters
Alnylam Pharmaceuticals' presentation at a major healthcare conference could impact investor sentiment and stock performance, highlighting its strategic direction and innovations in RNAi therapeutics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ALNY reported strong first-quarter results, with earnings and revenues exceeding estimates due to increased product sales.
Why It Matters
ALNY's strong first-quarter performance and revenue growth signal robust demand, potentially boosting investor confidence and indicating future profitability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Alnylam Pharmaceuticals will hold its Q1 2025 earnings conference call on May 1, 2025, at 8:30 AM ET. Key executives will present, with participation from major financial analysts.
Why It Matters
Alnylam Pharmaceuticals' upcoming earnings call will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ALNY Stock
What is Alnylam Pharmaceuticals Inc.'s (ALNY) stock forecast for 2025?
Based on our analysis of 44 Wall Street analysts, Alnylam Pharmaceuticals Inc. (ALNY) has a median price target of $328.00. The highest price target is $500.00 and the lowest is $212.00.
Is ALNY stock a good investment in 2025?
According to current analyst ratings, ALNY has 24 Buy ratings, 7 Hold ratings, and 2 Sell ratings. The stock is currently trading at $289.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALNY stock?
Wall Street analysts predict ALNY stock could reach $328.00 in the next 12 months. This represents a 13.1% increase from the current price of $289.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alnylam Pharmaceuticals Inc.'s business model?
Alnylam Pharmaceuticals leverages RNA interference (RNAi) technology to create innovative treatments that target and silence specific genes associated with various diseases. The company generates revenue through the development and commercialization of its therapeutics, as well as partnerships and collaborations with other pharmaceutical entities.
What is the highest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The highest price target for ALNY is $500.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 72.4% increase from the current price of $289.96.
What is the lowest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The lowest price target for ALNY is $212.00 from at , which represents a -26.9% decrease from the current price of $289.96.
What is the overall ALNY consensus from analysts for Alnylam Pharmaceuticals Inc.?
The overall analyst consensus for ALNY is bullish. Out of 44 Wall Street analysts, 24 rate it as Buy, 7 as Hold, and 2 as Sell, with a median price target of $328.00.
How accurate are ALNY stock price projections?
Stock price projections, including those for Alnylam Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 2:09 AM UTC